NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
NexGel (NXGL) had its price target lowered by Maxim Group from $6.00 to $2.00. They now have a "buy" rating on the stock.
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products [Yahoo! Finance]
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products